Blatch, Haysaw, MF4,
I might point point to you that about one year ago today on this very board, Neuro raised some informed criticism/skepticism to MDVN's Dimebon in AD (partnered with PFE), while many in the biotech investment community were going ga-ga over the "spectacular" results and the lucrative partnership. I can't think of a more clear-headed review of Dimebon than Neuro presented, and he made this presentation against a tidal wave of opinion that was treating Dimebon as some new wonder drug in AD.
(from a February 28, 2009 post here by Neuro):
"Medivation is hoping to achieve that claim for Dimebon. The issues specific to this trial IMHO are: 1) the short followup period, skeptics can argue that 18 months total is not enough to see whether patients who received Dimebon have truly durable effects upon the slope of deterioration. 2) My longstanding questioning of the Dimebon data is that it only tested 183 Russian patients, a small number in a limited demographic sample. Pfizer apparently decided that the study itself was not tainted by local corruption, but this was still a tiny sample upon which to build Phase III and a partnership."
MDVN was down 70% today, last time I looked. And it is probably going lower.
Bladerunner